COX2-dependent suppression of anticancer immunity

María Cecilia Lira,Lorenzo Galluzzi,Claire Vanpouille-Box
DOI: https://doi.org/10.1016/j.trecan.2024.05.006
Abstract:Prostaglandin E2 (PGE2) is well known to promote tumor progression by boosting cancer cell proliferation while inhibiting anticancer immunity. Recent data from Lacher et al. and Morotti et al. demonstrate that one of the mechanisms through which PGE2 suppresses tumor-targeting immune responses involves downregulation of interleukin 2 (IL2) receptors and consequent inhibition of mitochondrial metabolism in T cells.
What problem does this paper attempt to address?